Using targeted therapies at the end of life

Matthieu Delaye; Florian Scotte; Sabine Voisin-Saltiel; Elena Pavliuc; Laurence Vigouret-Viant; Sarah Dauchy; Christine Mateus

doi:10.1136/bmjspcare-2020-002529

Using targeted therapies at the end of life

Matthieu Delaye, Florian Scotte, Sabine Voisin-Saltiel, Elena Pavliuc, Laurence Vigouret-Viant, Sarah Dauchy, Christine Mateus

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The prescription of chemotherapy during the last weeks of a patient's life is a recognised criterion of decreasing quality of life but also survival. Targeted therapies have a particular efficiency and tolerance profile raising the question of their use in a palliative setting. Two patients were treated for a melanoma, at terminal stage, with poor efficiency of the symptomatic treatments. We introduced targeted therapies, which was previous treatments used in both patients.The evolution and benefits of the treatment was very different in our two patients and make us discuss the interest of targeted therapies in an end-of-life context and propose criteria for their maintenance or introduction in this indication. This discussion requires close collaboration between oncologists and palliative physicians and a very clear information given to patients and their relatives.

Original language	English
Pages (from-to)	356-358
Number of pages	3
Journal	BMJ Supportive and Palliative Care
Volume	12
Issue number	3
DOIs	https://doi.org/10.1136/bmjspcare-2020-002529
Publication status	Published - 1 Sept 2022

Keywords

end of life care
quality of life
supportive care
symptoms and symptom management

Access to Document

10.1136/bmjspcare-2020-002529

Cite this

@article{f49df1ae5bc54c2bbcff49623ae92987,

title = "Using targeted therapies at the end of life",

abstract = "The prescription of chemotherapy during the last weeks of a patient's life is a recognised criterion of decreasing quality of life but also survival. Targeted therapies have a particular efficiency and tolerance profile raising the question of their use in a palliative setting. Two patients were treated for a melanoma, at terminal stage, with poor efficiency of the symptomatic treatments. We introduced targeted therapies, which was previous treatments used in both patients.The evolution and benefits of the treatment was very different in our two patients and make us discuss the interest of targeted therapies in an end-of-life context and propose criteria for their maintenance or introduction in this indication. This discussion requires close collaboration between oncologists and palliative physicians and a very clear information given to patients and their relatives.",

keywords = "end of life care, quality of life, supportive care, symptoms and symptom management",

author = "Matthieu Delaye and Florian Scotte and Sabine Voisin-Saltiel and Elena Pavliuc and Laurence Vigouret-Viant and Sarah Dauchy and Christine Mateus",

note = "Publisher Copyright: {\textcopyright} ",

year = "2022",

month = sep,

day = "1",

doi = "10.1136/bmjspcare-2020-002529",

language = "English",

volume = "12",

pages = "356--358",

journal = "BMJ Supportive and Palliative Care",

issn = "2045-435X",

number = "3",

}

TY - JOUR

T1 - Using targeted therapies at the end of life

AU - Delaye, Matthieu

AU - Scotte, Florian

AU - Voisin-Saltiel, Sabine

AU - Pavliuc, Elena

AU - Vigouret-Viant, Laurence

AU - Dauchy, Sarah

AU - Mateus, Christine

N1 - Publisher Copyright: ©

PY - 2022/9/1

Y1 - 2022/9/1

N2 - The prescription of chemotherapy during the last weeks of a patient's life is a recognised criterion of decreasing quality of life but also survival. Targeted therapies have a particular efficiency and tolerance profile raising the question of their use in a palliative setting. Two patients were treated for a melanoma, at terminal stage, with poor efficiency of the symptomatic treatments. We introduced targeted therapies, which was previous treatments used in both patients.The evolution and benefits of the treatment was very different in our two patients and make us discuss the interest of targeted therapies in an end-of-life context and propose criteria for their maintenance or introduction in this indication. This discussion requires close collaboration between oncologists and palliative physicians and a very clear information given to patients and their relatives.

AB - The prescription of chemotherapy during the last weeks of a patient's life is a recognised criterion of decreasing quality of life but also survival. Targeted therapies have a particular efficiency and tolerance profile raising the question of their use in a palliative setting. Two patients were treated for a melanoma, at terminal stage, with poor efficiency of the symptomatic treatments. We introduced targeted therapies, which was previous treatments used in both patients.The evolution and benefits of the treatment was very different in our two patients and make us discuss the interest of targeted therapies in an end-of-life context and propose criteria for their maintenance or introduction in this indication. This discussion requires close collaboration between oncologists and palliative physicians and a very clear information given to patients and their relatives.

KW - end of life care

KW - quality of life

KW - supportive care

KW - symptoms and symptom management

UR - http://www.scopus.com/inward/record.url?scp=85092624006&partnerID=8YFLogxK

U2 - 10.1136/bmjspcare-2020-002529

DO - 10.1136/bmjspcare-2020-002529

M3 - Article

C2 - 32855229

AN - SCOPUS:85092624006

SN - 2045-435X

VL - 12

SP - 356

EP - 358

JO - BMJ Supportive and Palliative Care

JF - BMJ Supportive and Palliative Care

IS - 3

ER -

Using targeted therapies at the end of life

Abstract

Keywords

Access to Document

Other files and links

Cite this